GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Total Operating Expense

argenx SE (argenx SE) Total Operating Expense : $1,529 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is argenx SE Total Operating Expense?

argenx SE's Total Operating Expense for the three months ended in Dec. 2023 was $504 Mil. argenx SE's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $1,529 Mil.

argenx SE Total Operating Expense Historical Data

The historical data trend for argenx SE's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Total Operating Expense Chart

argenx SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 278.57 521.81 857.18 1,105.23 1,529.12

argenx SE Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 279.39 304.29 347.00 373.64 504.20

argenx SE Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,529 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Total Operating Expense Related Terms

Thank you for viewing the detailed overview of argenx SE's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Total Operating Expense
Comparable Companies
XBRU:UCB XBRU:TUB XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 BNTX BGNE SZSE:300122 ALNY
Traded in Other Exchanges
ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Website
https://www.argenx.com
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.